Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Gink­go Bioworks re­sizes the de­f­i­n­i­tion of go­ing big in biotech, rais­ing $2.5B in a record SPAC deal that weighs in with a whop­ping $15B-plus val­u­a­tion

Gink­go Bioworks ex­ecs al­ways thought big. But to­day should re­de­fine just how big an up­start biotech play­er can dream.

In the largest SPAC deal to clear the hur­dles to NYSE, the biotech that en­vi­sioned every­thing from re­mak­ing syn­thet­ic meat to a whole new ap­proach to de­vel­op­ing drugs has joined forces with one of the biggest dis­rup­tors in biotech to slam the Richter scale on deal­mak­ing.

Soon af­ter be­com­ing the dar­ling of the VC crew and clear­ing the bar on a $4 bil­lion val­u­a­tion, Gink­go — a syn­thet­ic biotech play­er out to re­pro­gram cells with in­dus­tri­al ef­fi­cien­cy — has now struck a deal to go pub­lic in the lat­est leviathan SPAC that sets its pre-mon­ey val­u­a­tion at $15 bil­lion. In one swift vault, Gink­go will com­bine with Har­ry Sloan’s Soar­ing Ea­gle Ac­qui­si­tion Corp. and leap in­to the pub­lic mar­kets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.